In summary, our findings define a DCP-mediated mechanism of Sorafenib inhibition on HCC, which is critical for the development of a targeted HCC therapy through inhibition of the Raf/MEK/ERK and PI3K/AKT/mTOR signaling pathways. The gene discussed is ACE; the disease is hepatocellular carcinoma.